Advertisement

Intensive Care Medicine

, Volume 33, Issue 3, pp 396–399 | Cite as

Increasing evidence that the risks of rhAPC may outweigh its benefits

  • Peter Q. Eichacker
  • Charles Natanson
Editorial

Sir: The surveys by Kanji et al. and Bertolini et al. in this issue of “Intensive Care Medicine” are important in providing further insights into the increased bleeding risks associated with recombinant human activated protein C (rhAPC) in clinical practice [1, 2]. Following approval of rhAPC in 2001, early surveys and post-marketing studies suggested that the risk of bleeding during clinical use might be greater than was noted in the original phase-3 trial [Recombinant Human Activated protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial; 3, 4, 5, 6]. Even more concerning, two additional randomized controlled sepsis trials conducted post-approval have failed to show any significant benefit with rhAPC [7, 8]. In light of increasing experience with rhAPC, the critical care community should reconsider whether the bleeding risks associated with this agent outweigh its purported benefit.

Increased bleeding with rhAPC has been a consistent finding in all sepsis trials conducted to...

References

  1. 1.
    Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observation study. Intensive Care Med DOI 10.1007/s00134-007-0555-9
  2. 2.
    Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of drotrecogin alfa (activated) in Italian intensive care units. The results of a nationwide survey. Intensive Care Med DOI 10.1007/s00134-007-0554-x
  3. 3.
    Steingrub J, Sanchez P, Zeckel M, Bates B, Qualy R (2003) Safety of drotrecogin alfa (activated): results of MERCURY, a retrospective multicenter observation study. Crit Care Med 31:A117Google Scholar
  4. 4.
    Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. NovationGoogle Scholar
  5. 5.
    Deans KJ, Minneci PC, Banks SM, Natanson C, Eichacker PQ (2004) Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med 32:2542–2543PubMedCrossRefGoogle Scholar
  6. 6.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopex-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al. (2001) Efficacy and safety of human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  7. 7.
    Abraham E, Laterre F, Garg R et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341PubMedCrossRefGoogle Scholar
  8. 8.
    Eisenberg P. Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of Drotrecogin alfa (activated) in pediatric severe sepsis (letter). http://www.fda.gov/medwatch/SAFETY/2005/xigris_dearhcp_4-21-05.htm. Accessed 5 July 2005
  9. 9.
    Eichacker PQ, Natanson C (2003) Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 31:S94–S96PubMedCrossRefGoogle Scholar
  10. 10.
    Eisenberg P. Important Drug Warning (letter) http://www.fda.gov/medwatch/SAFETY/2005/xigris_DHCP.htm. Accessed 5 July 2005
  11. 11.
    Vincent JL, Bernard GR, Beale R, Doig C, Putenson C, Dhainaut JF, Artigas A, Fumagelli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J, for the ENHANCE Study Group (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the Global Open-label Trial ENHANCE: further evidence for survival and safety. Crit Care Med 33:2266–2277PubMedCrossRefGoogle Scholar
  12. 12.
    Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C (2005) Reassessing recombinant human activated protein C for sepsis: time for a new randomized trial. Crit Care Med 33:2426–2428PubMedCrossRefGoogle Scholar
  13. 13.
    Hunter D (2006) First gather the data. N Engl J Med 354:329–331PubMedCrossRefGoogle Scholar
  14. 14.
    Vlahakes GJ (2006) The value of phase 4 clinical testing. N Engl J Med 354:413–415PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Critical Care Medicine, Building 10, Room 7D43, Clinical CenterNational Institutes of HealthBethesdaUSA

Personalised recommendations